a Department of Pediatric medicine, Linyi Central Hospital , Yishui , China.
Bioengineered. 2019 Dec;10(1):345-352. doi: 10.1080/21655979.2019.1652490.
This study aimed to detect serum miR-203 expression levels in AML and explore its potential clinical significance. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed to measure the serum miR-203 levels in 134 patients with AML and 70 healthy controls. The results demonstrated that serum miR-203 expression was significantly reduced in AML patients compared with healthy controls. Receiver operating characteristic curve (ROC) analysis revealed miR-203 could distinguish AML cases from normal controls. Low serum miR-203 levels were associated with worse clinical features, as well as poorer overall survival and relapse free survival of AML patients. Moreover, multivariate analysis confirmed low serum miR-203 expression to be an independent unfavorable prognostic predictor for AML. The bioinformatics analysis showed that the downstream genes and pathways of miR-203 was closely associated with tumorigenesis. Downregulation of miR-203 in AML cell lines upregulated the expression levels of oncogenic promoters such as CREB1, SRC and HDAC1. Thus, these findings demonstrated that serum miR-203 might be a promising biomarker for the diagnosis and prognosis of AML.
本研究旨在检测 AML 患者血清 miR-203 表达水平，并探讨其潜在的临床意义。采用定量逆转录聚合酶链反应（qRT-PCR）检测 134 例 AML 患者和 70 例健康对照者血清 miR-203 水平。结果表明，AML 患者血清 miR-203 表达水平明显低于健康对照组。受试者工作特征曲线（ROC）分析显示 miR-203 可区分 AML 病例与正常对照。低血清 miR-203 水平与 AML 患者更差的临床特征以及更差的总生存和无复发生存相关。此外，多变量分析证实低血清 miR-203 表达是 AML 的独立不良预后预测因子。生物信息学分析显示，miR-203 的下游基因和通路与肿瘤发生密切相关。在 AML 细胞系中下调 miR-203 可上调癌基因启动子如 CREB1、SRC 和 HDAC1 的表达水平。因此，这些发现表明血清 miR-203 可能是 AML 诊断和预后的有前途的生物标志物。
